Tumor endothelial marker 8 expression levels in dendritic cell-based cancer vaccines are related to clinical outcome

Cancer Immunology, Immunotherapy

Volumn 59, Issue 1, 2010, Pages 27-34

  Venanzi, Franco Maria ^a   Petrini, Massimiliano ^b   Fiammenghi, Laura ^b   Bolli, Elisabetta ^a   Granato, Anna Maria ^b   Ridolfi, Laura ^b   Gabrielli, Federica ^a   Barucca, Alessandra ^a   Concetti, Antonio ^a   Ridolfi, Ruggero ^b   Riccobon, Angela ^b  

^a UNIVERSITY OF CAMERINO   (Italy)

^b DEPARTMENT OF MEDICAL ONCOLOGY   (Italy)

Author keywords

Clinical outcome; Dendritic cells; Immunotherapy; Tumor endothelial marker 8

Indexed keywords

CANCER VACCINE; DENDRITIC CELL VACCINE; MESSENGER RNA; TUMOR ENDOTHELIAL MARKER 8; TUMOR MARKER; UNCLASSIFIED DRUG;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER GROWTH; CANCER IMMUNIZATION; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; DELAYED HYPERSENSITIVITY; FEMALE; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; KIDNEY CARCINOMA; MALE; MELANOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; TREATMENT OUTCOME; UPREGULATION;

ADULT; AGED; CANCER VACCINES; CARCINOMA, RENAL CELL; DENDRITIC CELLS; FEMALE; HUMANS; MALE; MELANOMA; MIDDLE AGED; NEOPLASM PROTEINS; RECEPTORS, CELL SURFACE; VACCINATION;

EID: 70350101292     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-009-0717-4     Document Type: Article

References (38)

1. E Gilboa 2007 DC-based cancer vaccines J Clin Invest 117 1195 1203 10.1172/JCI31205 17476349 1:CAS:528:DC%2BD2sXlt1Omtrc%3D (Pubitemid 46718404)
2. FO Nestle S Alijagic M Gilliet, et al. 1998 Vaccination of melanoma patients with peptide- or tumour lysate-pulsed dendritic cells Nat Med 4 328 332 10.1038/nm0398-328 9500607 1:CAS:528:DyaK1cXhs1Kisrc%3D (Pubitemid 28144092)
3. B Thurner I Haendle C Roder, et al. 1999 Vaccination with mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma J Exp Med 190 1669 1678 10.1084/jem.190.11.1669 10587357 1:CAS:528:DyaK1MXnvF2ntr0%3D (Pubitemid 30002348)
4. H Jonuleit A Giesecke-Tuettenberg T Tuting, et al. 2001 A comparison of two types of dendritic cell as adjuvants for the induction of melanoma-specific T-cell responses in humans following intranodal injection Int J Cancer 93 243 251 10.1002/ijc.1323 11410873 1:CAS:528:DC%2BD3MXltV2mtro%3D (Pubitemid 32574281)
5. K McLean RJ Buckanovich 2008 Myeloid cells functioning in tumour vascularization as a novel therapeutic target Transl Res 151 59 67 10.1016/j.trsl.2007.11.002 18201673 1:CAS:528:DC%2BD1cXptlektA%3D%3D
6. RS Kerbel 2008 Tumour angiogenesis N Engl J Med 358 2039 2049 10.1056/NEJMra0706596 18463380 1:CAS:528:DC%2BD1cXlsFyrtro%3D (Pubitemid 351656458)
7. C Murdoch M Muthana SB Coffelt, et al. 2008 The role of myeloid cells in the promotion of tumour angiogenesis Nat Rev Cancer 8 618 631 10.1038/nrc2444 18633355 1:CAS:528:DC%2BD1cXovV2lsrY%3D
8. E Gottfried M Kreutz S Haffner, et al. 2007 Differentiation of human tumour-associated dendritic cells into endothelial-like cells: an alternative pathway of tumour angiogenesis Scand J Immunol 65 329 335 10.1111/j.1365-3083. 2007.01903.x 17386023 1:CAS:528:DC%2BD2sXlsVCmsbc%3D (Pubitemid 46481100)
9. JR Conejo-Garcia RJ Buckanovich F Benencia, et al. 2005 Vascular leukocytes contribute to tumour vascularization Blood 105 679 681 10.1182/blood-2004-05-1906 15358628 1:CAS:528:DC%2BD2MXltlGgtA%3D%3D (Pubitemid 40070752)
10. B St Croix C Rago V Velculescu, et al. 2000 Genes expressed in human tumour endothelium Science 289 1197 1202 10.1126/science.289.5482.1197 10947988 1:CAS:528:DC%2BD3cXmt1WhsLo%3D (Pubitemid 30650733)
11. S Seaman J Stevens MY Yang, et al. 2007 Genes that distinguish physiological and pathological angiogenesis Cancer Cell 11 539 554 10.1016/j.ccr.2007.04.017 17560335 1:CAS:528:DC%2BD2sXmvVaksrk%3D (Pubitemid 46856908)
12. G Davies GH Cunnick RE Mansel, et al. 2004 Levels of expression of endothelial markers specific to tumour-associated endothelial cells and their correlation with prognosis in patients with breast cancer Clin Exp Metastasis 21 31 37 10.1023/B:CLIN.0000017168.83616.d0 15065600 1:CAS:528: DC%2BD2cXhsV2qu7g%3D (Pubitemid 38365655)
13. KA Rmali MC Puntis WG Jiang 2005 Prognostic values of tumour endothelial markers in patients with colorectal cancer World J Gastroenterol 11 1283 1286 15761964 1:CAS:528:DC%2BD2MXjt1yqsLs%3D
14. KA Bradley J Mogridge M Mourez, et al. 2001 Identification of the cellular receptor for anthrax toxin Nature 414 225 229 10.1038/n35101999 11700562 1:CAS:528:DC%2BD3MXosFahtrs%3D (Pubitemid 33051239)
15. HM Scobie GJ Rainey KA Bradley, et al. 2003 Human capillary morphogenesis protein 2 functions as an anthrax toxin receptor Proc Natl Acad Sci USA 100 5170 5174 10.1073/pnas.0431098100 12700348 1:CAS:528:DC%2BD3sXjs1yisLk%3D (Pubitemid 36542677)
16. C Premanandan MD Lairmore S Fernandez, et al. 2006 Quantitative measurement of anthrax toxin receptor messenger RNA in primary mononuclear phagocytes Microb Pathog 41 193 198 10.1016/j.micpath.2006.05.003 16854559 1:CAS:528:DC%2BD28Xps1Cjurw%3D (Pubitemid 44374294)
17. FJ Maldonado-Arocho JA Fulcher B Lee, et al. 2006 Anthrax oedema toxin induces anthrax toxin receptor expression in monocyte-derived cells Mol Microbiol 61 324 337 10.1111/j.1365-2958.2006.05232.x 16856939 1:CAS:528:DC%2BD28XotVeqtrs%3D (Pubitemid 44356566)
18. Venanzi FM, Gabrielli F, Riccobon A et al (2006) Tumour endothelial marker 8 (TEM8) gene expression in proangiogenic and cell migratory programs. Pezcoller Symposium. Tumour Microenvironment: heterotypic interactions, 27-29 June 2006, Trento, Italy. The Pezcoller Foundation Journal 26:40-41
19. R Ridolfi M Petrini L Fiammenghi, et al. 2006 Improved overall survival in dendritic cell vaccination-induced immunoreactive subgroup of advanced melanoma patients J Transl Med 4 36 10.1186/1479-5876-4-36 16914047 (Pubitemid 44472780)
20. AE Morelli AW Thomson 2003 Dendritic cells under the spell of prostaglandins Trends Immunol 24 108 111 10.1016/S1471-4906(03)00023-1 12615202 1:CAS:528:DC%2BD3sXhs1Wgtrk%3D (Pubitemid 36263091)
21. DK Banerjee MV Dhodapkar E Matayeva, et al. 2006 Expansion of FOXP3 high regulatory T cells by human dendritic cells (DCs) in vitro and after injection of cytokine-matured DCs in myeloma patients Blood 108 2655 2661 10.1182/blood-2006-03-011353 16763205 1:CAS:528:DC%2BD28XhtFWgtL%2FO (Pubitemid 44777001)
22. M Wobser H Voigt R Houben, et al. 2007 Dendritic cell based antitumour vaccination: impact of functional indoleamine 2, 3-dioxygenase expression Cancer Immunol Immunother 56 1017 1024 10.1007/s00262-006-0256-1 17195079 1:CAS:528:DC%2BD2sXks1agsbs%3D (Pubitemid 46675300)
23. P Sinha VK Clements AM Fulton, et al. 2007 Prostaglandin E2 promotes tumour progression by inducing myeloid-derived suppressor cells Cancer Res 67 4507 4513 10.1158/0008-5472.CAN-06-4174 17483367 1:CAS:528:DC%2BD2sXltVyrtrY%3D (Pubitemid 46815102)
24. E Riboldi T Musso E Moroni, et al. 2005 Cutting edge: proangiogenic properties of alternatively activated dendritic cells J Immunol 175 2788 2792 16116163 1:CAS:528:DC%2BD2MXos1Gis7g%3D
25. Q Xu ED Hesek M Zeng 2007 Transcriptional stimulation of anthrax toxin receptors by anthrax edema toxin and Bacillus anthracis Sterne spore Microb Pathog 43 37 45 10.1016/j.micpath.2007.03.002 17459655 1:CAS:528: DC%2BD2sXkvFOmsrg%3D (Pubitemid 46678645)
26. M Novatchkova F Eisenhaber 2001 Can Molecular mechanisms of biological processes be extracted from expression profiles? Case study: endothelial contribution to tumour-induced angiogenesis BioEssay 23 1159 1175 10.1002/bies.10013 1:CAS:528:DC%2BD38XksFOktw%3D%3D (Pubitemid 34021019)
27. A Nanda EB Carson-Walter S Seaman, et al. 2004 TEM8 interacts with the cleaved C5 domain of collagen alpha 3(VI) Cancer Res 64 817 820 10.1158/0008-5472.CAN-03-2408 14871805 1:CAS:528:DC%2BD2cXhtFCgtL8%3D (Pubitemid 38176877)
28. KA Hotchkiss CM Basile SC Spring, et al. 2005 TEM8 expression stimulates endothelial cell adhesion and migration by regulating cell-matrix interactions on collagen Exp Cell Res 305 133 144 10.1016/j.yexcr.2004.12.025 15777794 1:CAS:528:DC%2BD2MXitlCjsb0%3D (Pubitemid 40380660)
29. E Werner AP Kowalczyk V Faundez 2006 Anthrax toxin receptor 1/tumour endothelium marker 8 mediates cell spreading by coupling extracellular ligands to the actin cytoskeleton J Biol Chem 281 23227 23236 10.1074/jbc.M603676200 16762926 1:CAS:528:DC%2BD28XnvVWjtbY%3D (Pubitemid 44242353)
30. HF Huan XW Hu JL Chen, et al. 2007 Antitumour activities of TEM8-Fc: an engineered antibody-like molecule targeting tumour endothelial marker 8 J Natl Cancer Inst 99 1551 1555 10.1093/jnci/djm132 1:CAS:528:DC%2BD2sXhtlCqsbnM (Pubitemid 351767233)
31. A Nanda B St Croix 2004 Tumour endothelial markers: new targets for cancer therapy Curr Opin Oncol 16 44 49 10.1097/00001622-200401000-00009 14685092 1:CAS:528:DC%2BD3sXpvVKrt7s%3D (Pubitemid 38703471)
32. A Bolander M Agnarsdóttir G Wagenius, et al. 2008 Serological and immunohistochemical analysis of S100 and new derivatives as markers for prognosis in patients with malignant melanoma Melanoma Res 18 412 419 10.1097/CMR.0b013e328315c690 19011512 1:CAS:528:DC%2BD1cXhtlyqtLvO
33. S Ugurel N Bell A Sucker, et al. 2005 Tumour type M2 pyruvate kinase (TuM2-PK) as a novel plasma tumour marker in melanoma Int J Cancer 117 825 830 10.1002/ijc.21073 15957165 1:CAS:528:DC%2BD2MXht1ShsbfN (Pubitemid 41598835)
34. FO Nestle A Farkas C Conrad 2005 Dendritic-cell-based therapeutic vaccination against cancer Curr Opin Immunol 17 163 169 10.1016/j.coi.2005.02. 003 15766676 1:CAS:528:DC%2BD2MXit1ChtL4%3D (Pubitemid 40343103)
35. JC Arroyo F Gabilondo L Llorente, et al. 2004 Immune response induced in vitro by CD16- and CD16+ monocyte-derived dendritic cells in patients with metastatic renal cell carcinoma treated with dendritic cell vaccines J Clin Immunol 24 86 96 10.1023/B:JOCI.0000018067.71622.fb 14997038 (Pubitemid 38375799)
36. S Nagaraj DI Gabrilovich 2008 Tumour escape mechanism governed by myeloid-derived suppressor cells Cancer Res 68 2561 2563 10.1158/0008-5472.CAN- 07-6229 18413722 1:CAS:528:DC%2BD1cXks1Git7s%3D (Pubitemid 351556251)
37. P Serafini I Borrello V Bronte 2006 Myeloid suppressor cells in cancer: recruitment, phenotype, properties, and mechanisms of immune suppression Semin Cancer Biol 16 53 65 10.1016/j.semcancer.2005.07.005 16168663 1:CAS:528:DC%2BD28XotVCmuw%3D%3D (Pubitemid 43139709)
38. S Ostrand-Rosenberg P Sinha 2009 Myeloid-derived suppressor cells: linking inflammation and cancer J Immunol 182 4499 4506 10.4049/jimmunol.0802740 19342621 1:CAS:528:DC%2BD1MXjvFOjtrg%3D